M&A Archives -

Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the

Pfizer vaults into sickle cell market as GBT deal confirmed

https://pharmaphorum.com/news/pfizer-vaults-into-sickle-cell-market-as-gbt-deal-confirmed/

News/ News/ Sales and Marketing

Pfizer bid for sickle cell drug developer GBT said to be imminent

Phil Taylor Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease 0 Comment

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral

Pfizer bid for sickle cell drug developer GBT said to be imminent

https://pharmaphorum.com/news/pfizer-bid-for-sickle-cell-drug-developer-gbt-said-to-be-imminent/

News/ News/ R&D

Gilead snaps up MiroBio and its checkpoint agonists for $405m

Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a

Gilead snaps up MiroBio and its checkpoint agonists for $405m

https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/

News/ News/ R&D

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

Phil Taylor Amgen, ChemoCentryx, Immunology and inflammation, M&A, nephrology, Tavneos 0 Comment

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

https://pharmaphorum.com/news/amgen-splashes-out-on-chemocentryx-and-its-blockbuster-hopeful/

News/ News/ R&D

Labcorp unveils plan to spin out clinical development business

Phil Taylor clinical research, CRO, Labcorp, M&A, outsourcing 0 Comment

Laboratory Corp of America (Labcorp) has announced that it plans to separate its clinical development business into an

Labcorp unveils plan to spin out clinical development business

https://pharmaphorum.com/news/labcorp-unveils-plan-to-spin-out-clinical-development-business/

News/ News/ Sales and Marketing

Ginkgo buys Zymergen, but may shed drug discovery business

Phil Taylor biotechnology, Ginkgo Bioworks, M&A, synthetic biology, Zymergen 0 Comment

Zymergen’s brand new plan to shift from a synthetic biology specialist to a drug discovery player has come

Ginkgo buys Zymergen, but may shed drug discovery business

https://pharmaphorum.com/news/ginkgo-buys-zymergen-but-may-shed-drug-discovery-business/

Digital/ News/ News/ News/ Patients

Amazon ratchets up its health ambitions, buying US primary care group

Phil Taylor Amazon, digital health, M&A, One Medical Group, telehealth, telemedicine 0 Comment

Amazon has accelerated its expansion into the healthcare sector with an all-cash deal to acquire One Medical, a

Amazon ratchets up its health ambitions, buying US primary care group

https://pharmaphorum.com/news/amazon-ratchets-up-its-health-ambitions-buying-us-primary-care-group/

News/ News/ Sales and Marketing

Novartis faces tougher decision on Sandoz, as finances recover

Phil Taylor biosimilars, Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis said this morning that it remains on course to make a decision on the future of its

Novartis faces tougher decision on Sandoz, as finances recover

https://pharmaphorum.com/news/novartis-faces-tougher-decision-on-sandoz-as-finances-recover/

News/ News/ News/ Oncology/ Sales and Marketing

Commission can rule on Illumina, Grail merger, says EU court

Phil Taylor antitrust, diagnostics, European Commission, Galleri, Grail, Illumina, litigation, M&A, Oncology 0 Comment

Illumina’s attempt to prevent the European Commission from carrying out an antitrust review of its $8 billion takeover

Commission can rule on Illumina, Grail merger, says EU court

https://pharmaphorum.com/news/commission-can-rule-on-illumina-grail-merger-says-eu-court/

Trending

M&A

Login